<DOC>
	<DOCNO>NCT00631137</DOCNO>
	<brief_summary>RATIONALE : Testosterone gel may effective prevent lessen muscle weakness cause steroid therapy men receive glucocorticoid newly diagnose high-grade glioma . PURPOSE : This randomized clinical trial study well testosterone gel work prevent weakness cause steroid therapy men receive glucocorticoid newly diagnose high-grade glioma .</brief_summary>
	<brief_title>Testosterone Gel Preventing Weakness Caused Steroid Therapy Men Receiving Glucocorticoids Newly Diagnosed High-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine daily administration testosterone gel prevent development reduce severity muscle weakness men receive glucocorticoid newly diagnose high-grade glioma . Secondary - To compare difference percent change baseline time functional test ( TFT ) patient treat testosterone gel . - To compare difference percent change baseline activity daily live assess Health Assessment Questionnaire-Disability Index ( HAQ-DI ) patient treat testosterone gel . - To compare difference percent change baseline leg muscle mass assess CT scan imaging patient treat testosterone gel . - To estimate side effect testosterone gel patient . OUTLINE : Patients stratify accord daily glucocorticoid dose ( &lt; 16 mg/day v ≥ 16 mg/day ) , Karnofsky performance status ( ≤ 80 % v &gt; 80 % ) , age ( ≤ 50 year age vs &gt; 50 year age ) . Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients receive oral whey protein powder daily 7 month . - Arm II ( treatment ) : Patients apply topical testosterone gel shoulder , upper chest , forearm daily 7 month . Patients undergo strength test functional testing ( TFT ) complete activity daily live questionnaire baseline 1 , 3 , 5 , 7 month . Patients also undergo CT scan leg laboratory test baseline 3 7 month . Testosterone level obtain baseline 1 , 3 , 7 month . Patients complete daily log glucocorticoid dose affirm compliance therapy . Major clinical event related underlying tumor ( i.e. , surgery , radiotherapy , initiate chemotherapy , concurrent antiepileptic therapy , deep vein thrombosis , pulmonary embolism , transfusion , seizure , pneumonia , form infection ) also record .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose highgrade glioma , include follow subtypes : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Requires dexamethasone dose &gt; 4 mg/day control symptom tumorrelated edema time study enrollment AND stable dose steroid ≥ 5 day prior study enrollment Completed ≥ 80 % prescribed radiotherapy Hypogonadal , define serum testosterone level &lt; 350 ng/dL No history prostate breast cancer No benign prostatic hypertrophy require therapy OR AUA score ≥ 8 PSA ≤ 4 ng/mL PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Able keep daily record care provider agree keep daily record drug administration No clinical history congestive heart failure require therapy No psychotic disorder require active treatment No structured exercise program involve exercise &gt; 3 hours/week No polycythemia ( i.e. , hematocrit &gt; 52 % ) PRIOR CONCURRENT THERAPY : More 6 month since prior androgen therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>musculoskeletal complication</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>